PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshepatic porphyrias
MeSH D017094 - hepatic porphyrias
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008107:Liver diseases
2 Companies
2 Drugs
$
Success rate
D012873:Genetic skin diseases
4 Companies
4 Drugs
$
Success rate
D011164:Porphyrias
0 Companies
0 Drugs
Success rate
D017094: 
Hepatic porphyrias
1 Company
1 Drug
$
Success rate
D017118:Acute intermittent porphyria
34 Companies
1 Drug
$
Success rate
D017119:Porphyria cutanea tarda
15 Companies
1 Drug
$
Success rate
D017121:Hepatoerythropoietic porphyria
0 Companies
0 Drugs
Success rate
D046349:Hereditary coproporphyria
0 Companies
0 Drugs
Success rate
D046350:Variegate porphyria
0 Companies
0 Drugs
Success rate
D046351:Erythropoietic protoporphyria
1 Company
1 Drug
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Alnylam PharmaceuticalsGivosiran Givlaari  2020-03-02 $229.401 M Q2/23-Q1/24 
Clinical Trials
Historical Success Rate
Phase 1
100%
2/2
Phase 2
0%
0/0
Phase 3
100%
4/4
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Alnylam Pharmaceuticals
Givosiran,
Givosiran sodium,
Losartan,
Sodium chloride
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use